 Michelle Fullard
Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 20 | 2026 | 601 | 4.630 |
Why?
| | Deep Brain Stimulation | 3 | 2026 | 220 | 1.540 |
Why?
| | Olfaction Disorders | 4 | 2021 | 70 | 1.210 |
Why?
| | Cognitive Dysfunction | 5 | 2021 | 468 | 0.910 |
Why?
| | Patient Acceptance of Health Care | 2 | 2026 | 883 | 0.900 |
Why?
| | Decision Support Techniques | 2 | 2026 | 480 | 0.850 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2020 | 183 | 0.510 |
Why?
| | Decision Making | 1 | 2024 | 982 | 0.510 |
Why?
| | Patient Readmission | 2 | 2020 | 772 | 0.500 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 190 | 0.450 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2020 | 376 | 0.420 |
Why?
| | Vitamin D | 1 | 2017 | 404 | 0.400 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 337 | 0.400 |
Why?
| | Length of Stay | 1 | 2020 | 1350 | 0.400 |
Why?
| | Patient Discharge | 1 | 2020 | 995 | 0.380 |
Why?
| | Aged | 17 | 2026 | 26215 | 0.370 |
Why?
| | Sex Characteristics | 1 | 2017 | 789 | 0.360 |
Why?
| | Medicare | 4 | 2019 | 904 | 0.350 |
Why?
| | Healthcare Disparities | 2 | 2019 | 736 | 0.350 |
Why?
| | Middle Aged | 13 | 2026 | 36302 | 0.250 |
Why?
| | Dementia | 2 | 2023 | 328 | 0.240 |
Why?
| | Endarterectomy, Carotid | 1 | 2026 | 64 | 0.230 |
Why?
| | Alzheimer Disease | 2 | 2023 | 630 | 0.220 |
Why?
| | Male | 17 | 2026 | 73003 | 0.220 |
Why?
| | Carotid Stenosis | 1 | 2026 | 107 | 0.220 |
Why?
| | Aged, 80 and over | 6 | 2020 | 8346 | 0.220 |
Why?
| | Female | 16 | 2026 | 79035 | 0.210 |
Why?
| | Patient Selection | 2 | 2026 | 739 | 0.200 |
Why?
| | Humans | 22 | 2026 | 145763 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 364 | 0.190 |
Why?
| | Lewy Body Disease | 1 | 2023 | 33 | 0.180 |
Why?
| | Cannabidiol | 1 | 2024 | 142 | 0.170 |
Why?
| | Endovascular Procedures | 1 | 2026 | 390 | 0.170 |
Why?
| | Dronabinol | 1 | 2024 | 249 | 0.160 |
Why?
| | Disease Progression | 5 | 2025 | 2865 | 0.160 |
Why?
| | United States | 6 | 2024 | 16123 | 0.150 |
Why?
| | Cholinergic Antagonists | 1 | 2019 | 24 | 0.140 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 47 | 0.140 |
Why?
| | Leukoencephalopathies | 1 | 2018 | 24 | 0.140 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 203 | 0.140 |
Why?
| | Medication Errors | 1 | 2019 | 85 | 0.140 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1197 | 0.130 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.130 |
Why?
| | Cohort Studies | 3 | 2017 | 6032 | 0.130 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2017 | 59 | 0.130 |
Why?
| | Databases, Factual | 2 | 2020 | 1491 | 0.130 |
Why?
| | White Matter | 1 | 2018 | 155 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2019 | 288 | 0.120 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1330 | 0.120 |
Why?
| | Biomarkers | 2 | 2019 | 4302 | 0.120 |
Why?
| | REM Sleep Behavior Disorder | 1 | 2016 | 17 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1512 | 0.110 |
Why?
| | tau Proteins | 1 | 2016 | 105 | 0.110 |
Why?
| | Risk | 1 | 2017 | 923 | 0.110 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 1137 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2967 | 0.110 |
Why?
| | Cognition Disorders | 1 | 2018 | 544 | 0.100 |
Why?
| | Salivary Ducts | 1 | 2013 | 2 | 0.100 |
Why?
| | Myelitis, Transverse | 1 | 2013 | 4 | 0.100 |
Why?
| | Carcinoma, Ductal | 1 | 2013 | 10 | 0.100 |
Why?
| | Parotid Neoplasms | 1 | 2013 | 15 | 0.100 |
Why?
| | Spinal Cord Neoplasms | 1 | 2013 | 41 | 0.100 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 245 | 0.100 |
Why?
| | Proteomics | 1 | 2019 | 1188 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2139 | 0.090 |
Why?
| | Incidence | 1 | 2017 | 2933 | 0.080 |
Why?
| | Prevalence | 1 | 2017 | 2874 | 0.080 |
Why?
| | Cognition | 1 | 2018 | 1271 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 4329 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2026 | 1420 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2969 | 0.060 |
Why?
| | Exercise | 1 | 2018 | 2205 | 0.060 |
Why?
| | Age of Onset | 1 | 2025 | 557 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10917 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2024 | 176 | 0.050 |
Why?
| | Community-Based Participatory Research | 1 | 2024 | 168 | 0.050 |
Why?
| | Patient Participation | 1 | 2026 | 446 | 0.050 |
Why?
| | Minority Groups | 1 | 2024 | 285 | 0.040 |
Why?
| | Educational Status | 1 | 2024 | 470 | 0.040 |
Why?
| | Stents | 1 | 2026 | 564 | 0.040 |
Why?
| | Disease Management | 1 | 2025 | 653 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2020 | 17325 | 0.040 |
Why?
| | Adult | 3 | 2020 | 40872 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2026 | 11793 | 0.040 |
Why?
| | Smell | 1 | 2021 | 126 | 0.040 |
Why?
| | Amidohydrolases | 1 | 2019 | 31 | 0.040 |
Why?
| | Osteopontin | 1 | 2019 | 35 | 0.040 |
Why?
| | Drug Incompatibility | 1 | 2019 | 1 | 0.040 |
Why?
| | Proteoglycans | 1 | 2019 | 112 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2064 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2019 | 156 | 0.030 |
Why?
| | Social Class | 1 | 2019 | 264 | 0.030 |
Why?
| | Neurodegenerative Diseases | 1 | 2019 | 143 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 1036 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 729 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 156 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 486 | 0.030 |
Why?
| | Resistance Training | 1 | 2018 | 186 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1662 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 876 | 0.020 |
Why?
| | Thoracic Vertebrae | 1 | 2013 | 83 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 305 | 0.020 |
Why?
| | Syndrome | 1 | 2013 | 381 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1850 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3416 | 0.020 |
Why?
| | Radiography | 1 | 2013 | 853 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5922 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5428 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3915 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 8075 | 0.010 |
Why?
|
|
Fullard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|